Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN).

Joshua A TobinShivang JoshiJanet H FordRussell M NicholsShonda A FosterDustin RuffHolland C DetkeSheena K Aurora
Published in: Journal of medical economics (2022)
Treatment with galcanezumab resulted in significant reductions in headache medication overuse and migraine headache days requiring acute medication use, with notable reductions in migraine-specific HCRU.